ArticleiLIVER2026
Comparison of surgical treatment versus transcatheter arterial chemoembolization combined with systemic treatment for spontaneously ruptured hepatocellular carcinoma.
Article in iLIVER, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aims: This study aimed to evaluate the efficacy of hepatectomy versus transcatheter arterial chemoembolization (TACE), both combined with targeted therapy and immunotherapy, in patients with spontaneously ruptured hepatocellular carcinoma (HCC). Methods: We retrospectively reviewed the data of 78 patients with spontaneously ruptured HCC. Patients received targeted therapy and immunotherapy and were stratified into the hepatectomy group ( Results: Multivariable analysis identified TACE (hazard ratio [HR]: 3.394, 95% confidence interval [CI]: 1.777-6.483 for overall survival [OS]; HR: 4.763, 95% CI: 2.601-8.723 for event-free survival [EFS] and vascular invasion (VI) (HR: 3.141, 95% CI: 1.554-6.346 for OS; HR: 3.277, 95% CI: 1.713-6.269 for EFS) as independent risk factors for OS and EFS. An AFP level > 400 ng/mL (HR: 1.944, 95% CI: 1.075-3.518) was identified as an independent risk factor for EFS. The 1-, 3-, and 5-year OS rates for the hepatectomy and TACE groups were 88.4%, 53.9%, and 31.8% and 71.4%, 22.9%, and NA ( Conclusions: Compared with TACE combined with targeted therapy and immunotherapy, hepatectomy combined with targeted therapy and immunotherapy is a safe and effective treatment for patients with spontaneously ruptured HCC. It does not increase the incidence of complications and offers improved long-term prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.